Characteristics of HSCT patients
| Characteristics . | . | No cGVHD, n = 85 . | cGVHD, n = 106 . | cGVHD-T, n = 93 . |
|---|---|---|---|---|
| Age, y | Medium | 56 | 61 | 58 |
| Range | 22-75 | 30-77 | 26-75 | |
| Sex, % | F | 47 (55) | 56 (53) | 40 (43) |
| M | 38 (45) | 50 (47) | 53 (57) | |
| Disease, % | AML/MDS | 65 (76) | 85 (80) | 63 (68) |
| Others | 20 (24) | 21 (20) | 30 (32) | |
| Conditioning regimen, % | MAC | 35 (41) | 36 (34) | 32 (34) |
| RIC | 50 (59) | 70 (66) | 61 (66) | |
| Donor type, % | MRD | 37 (44) | 29 (27) | 31 (33) |
| MUD | 42 (49) | 58 (55) | 49 (53) | |
| MMUD | 6 (7) | 19 (18) | 13 (14) | |
| GVHD prophylaxis, % | Tac-MTX | 35 (41) | 41 (39) | 31 (33) |
| Tac-Sir | 12 (14) | 14 (13) | 25 (27) | |
| Tac-Sir-MTX | 27 (32) | 41 (39) | 30 (32) | |
| others | 11 (13) | 10 (9) | 7 (8) | |
| Months from HSCT to sample collection | Median | 22 | 24 | 20 |
| Range | 12-164 | 6-116 | 6-140 |
| Characteristics . | . | No cGVHD, n = 85 . | cGVHD, n = 106 . | cGVHD-T, n = 93 . |
|---|---|---|---|---|
| Age, y | Medium | 56 | 61 | 58 |
| Range | 22-75 | 30-77 | 26-75 | |
| Sex, % | F | 47 (55) | 56 (53) | 40 (43) |
| M | 38 (45) | 50 (47) | 53 (57) | |
| Disease, % | AML/MDS | 65 (76) | 85 (80) | 63 (68) |
| Others | 20 (24) | 21 (20) | 30 (32) | |
| Conditioning regimen, % | MAC | 35 (41) | 36 (34) | 32 (34) |
| RIC | 50 (59) | 70 (66) | 61 (66) | |
| Donor type, % | MRD | 37 (44) | 29 (27) | 31 (33) |
| MUD | 42 (49) | 58 (55) | 49 (53) | |
| MMUD | 6 (7) | 19 (18) | 13 (14) | |
| GVHD prophylaxis, % | Tac-MTX | 35 (41) | 41 (39) | 31 (33) |
| Tac-Sir | 12 (14) | 14 (13) | 25 (27) | |
| Tac-Sir-MTX | 27 (32) | 41 (39) | 30 (32) | |
| others | 11 (13) | 10 (9) | 7 (8) | |
| Months from HSCT to sample collection | Median | 22 | 24 | 20 |
| Range | 12-164 | 6-116 | 6-140 |
AML, acute myeloid leukemia; cGVHD, chronic GVHD patients as described in “Materials and methods”; cGVHD-T, chronic GVHD patients receiving intensive treatments described in “Materials and methods”; F, female; M, male; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMUD, mismatched unrelated donor; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; RIC, reduced-intensity conditioning; Sir, rapamycin; Tac, tacrolimus.